Your session is about to expire
← Back to Search
GRT-C901 for Non-Small Cell Lung Cancer
Study Summary
This trial is testing a new cancer vaccine in combination with two immunotherapy drugs. The goal is to see if it is safe and effective in treating patients with metastatic non-small cell lung cancer, microsatellite stable colorectal cancer, gastroesophageal adenocarcinoma, and metastatic urothelial cancer.
- Non-Small Cell Lung Cancer
- Colorectal Cancer
- Gastroesophageal Adenocarcinoma
- Bladder Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the capacity of participants in this trial?
"This specific trial is no longer actively looking for participants as the last edit was made on August 31st 2021. However, there are still 2129 studies that seek to understand gastroesophageal reflux disease and 765 trials related to GRT-C901 currently recruiting."
What maladies can be alleviated by GRT-C901?
"GRT-C901 is often given to patients who have previously attempted anti-angiogenic therapy, as well as those with a variety of other maladies like melanoma and squamous cell carcinoma."
What past research has been conducted utilizing GRT-C901?
"As of today, there are 765 active clinical trials researching GRT-C901. Of those experiments, 86 have advanced to Phase 3 and the vast majority (42755) are taking place in Pittsburgh, Pennsylvania."
Are there still openings for individuals to participate in this experiment?
"This clinical trial is now defunct, as the last update was posted on August 31st 2021. For those seeking alternate studies, there are currently 2129 trials actively recruiting patients with gastroesophageal reflux disease and 765 trials for GRT-C901 that require participants."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger